Sector Expert: Joseph Gomes

Noble Capital Markets

Joe Gomes is a senior research analyst at Noble Capital Markets. Gomes has over 20 years experience as a generalist analyst covering the small-to-mid cap space. Before joining the company, he was senior equity analyst for Wm. Smith & Co. His prior equity research experience includes stints at Oppenheimer & Co., McGinn Smith & Co., where he spearheaded the development of an institutional research effort, C.L. King & Co., Federal Filings, and 13D Research. Gomes is a Chartered Financial Analyst and holds an MBA in Finance from Pace University and a BS in Agricultural Economics from Cornell University.



Recent Quotes

"STEM launched the Budee Cannabis Delivery app, in Apple's App Store."

— Joseph Gomes, Noble Capital Markets (10/13/21)
more >

"VIV entered an eight-year distribution agreement with AB Vista."

— Joseph Gomes, Noble Capital Markets (10/7/21)
more >

"VIV's pipeline continues to expand."

— Joseph Gomes, Noble Capital Markets (9/30/21)
more >

"STEM received a license to open a distribution hub in Mendota, Calif."

— Joseph Gomes, Noble Capital Markets (9/21/21)
more >

"STEM acquired a cannabis extraction company and two dispensaries."

— Joseph Gomes, Noble Capital Markets (9/21/21)
more >

"STEM continued to build momentum during Q3 FY21."

— Joseph Gomes, Noble Capital Markets (8/18/21)
more >

"Momentum continues to build for VIV."

— Joseph Gomes, Noble Capital Markets (6/4/21)
more >

"STEM's Q2 FY21 gross revenue was $12.4M, net revenue was $10.5M."

— Joseph Gomes, Noble Capital Markets (5/24/21)
more >

more comments

"STEM's expansion is positive and in line with company growth plans."

— Joseph Gomes, Noble Capital Markets (5/5/21)
more >

"We believe VIV is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

— Joseph Gomes, Noble Capital Markets (5/4/21)
more >

"VIV received a purchase order for 4.4 mt of OxC-beta Livestock."

— Joseph Gomes, Noble Capital Markets (4/26/21)
more >

"Another manuscript on benefits of VIV's OxC-beta will be published."

— Joseph Gomes, Noble Capital Markets (3/5/21)
more >

"We are initiating research coverage on VIV with an Outperform rating."

— Joseph Gomes, Noble Capital Markets (3/1/21)
more >

fewer comments


Due to permission requirements, not all quotes are shown.